CONSOLIDATED BALANCE SHEETS (UNAUDITED) (USD $) In Millions, unless otherwise specified	Jun. 30, 2013	Dec. 31, 2012
Current Assets:
Cash and cash equivalents	$ 1,821	$ 1,656
Marketable Securities, Current	978	1,173
Receivables	3,406	3,083
Inventories	1,785	1,657
Deferred income taxes	1,960	1,597
Prepaid expenses and other	536	355
Total Current Assets	10,486	9,521
Property, plant and equipment	5,228	5,333
Goodwill	7,646	7,635
Other intangible assets	8,370	8,778
Deferred income taxes	195	203
Marketable Securities, Noncurrent	3,223	3,523
Other assets	1,104	904
Total Assets	36,252	35,897
Current Liabilities:
Short-term borrowings and current portion of long-term debt	764	826
Accounts payable	2,346	2,202
Accrued expenses	2,423	2,573
Deferred income	986	825
Accrued rebates and returns	1,017	1,054
Income taxes payable	212	193
Dividends payable	606	606
Total Current Liabilities	8,354	8,279
Pension, postretirement, and postemployment liabilities	826	1,882
Deferred income	4,146	4,024
Income taxes payable	644	648
Deferred income taxes	818	383
Other liabilities	649	475
Long-term debt	6,442	6,568
Total Liabilities	21,879	22,259
Commitments and contingencies (Note 17)
Bristol-Myers Squibb Company Shareholders' Equity:
Preferred stock, $2 convertible series, par value $1 per share: Authorized 10 million shares; issued and outstanding 4,485 in 2013 and 5,117 in 2012, liquidation value of $50 per share	0	0
Common stock, par value of $0.10 per share: Authorized 4.5 billion shares; 2.2 billion issued in both 2013 and 2012	221	221
Capital in excess of par value of stock	1,975	2,694
Accumulated other comprehensive loss	(2,520)	(3,202)
Retained earnings	32,715	32,733
Less cost of treasury stock - 562 million common shares in 2013 and 570 million in 2012	(18,020)	(18,823)
Total Bristol-Myers Squibb Company Shareholders' Equity	14,371	13,623
Noncontrolling interest	2	15
Total Equity	14,373	13,638
Total Liabilities and Equity	$ 36,252	$ 35,897